Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
35 Results for "
D1 domain
" in MedChemExpress (MCE) Product Catalog:
Products (35)
35 Results for "D1 domain" in MCE Product Catalog:
8
Target:
Research Areas:
8
8 Publications Verification
Cat. No.: HY-P0117A
CAS No.: 1834571-04-8
Synonyms: Tat-NR2Bct TFA; NA-1 TFA
Target:
Research Areas:
3
3 Cited Publications
Target:
Research Areas:
NAZ2329, the first cell-permeable inhibitor of R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), allosterically and preferentially inhibits PTPRZ (IC50=7.5 µM for hPTPRZ1) and PTPRG (IC50=4.8 µM for hPTPRG) over other PTPs. NAZ2329 binds to the active D1 domain and more potently inhibits PTPRZ-D1 fragment (IC50 of 1.1 µM) than the whole intracellular (D1 + D2) fragment (IC50 of 7.5 µM). NAZ2329 can effectively inhibit tumor growth of the glioblastoma cells and suppress stem cell-like properties .
3
3 Cited Publications
Cat. No.: HY-P72337
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CGAS; D4; Prev. C6orf150; DANGER Family Member 4; Prev. MB21D1; CGAMP Synthase; H-CGAS; Chromosome 6 Open Reading Frame 150; Mab-21 domain-Containing Protein 1; Protein MB21D1; 2'3'-CGAMP Synthase; Cyclic GMP-AMP Synthase; Mab-21 domain Containing 1
1
1 Cited Publications
Cat. No.: HY-P71597
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CGAS; D4; Prev. C6orf150; DANGER Family Member 4; Prev. MB21D1; CGAMP Synthase; H-CGAS; Chromosome 6 Open Reading Frame 150; Mab-21 domain-Containing Protein 1; Protein MB21D1; 2'3'-CGAMP Synthase; Cyclic GMP-AMP Synthase; Mab-21 domain Containing 1
Cat. No.: HY-172085
CAS No.: 3099543-90-2
Target:
Research Areas:
SH514 is an orally active IRF4 inhibitor (IC50 = 2.63 μM). SH514 binds to the IRF4-DBD domain, thereby inhibiting the interaction of IRF4 protein with DNA (KD = 1.28 μM). SH514 can inhibit the proliferation of IRF4-high-expressing NCI-H929 and MM.1R cells, and displays no cytotoxicity for normal cells. SH514 significantly downregulates the expression of IRF4 downstream target genes concentration-dependently. SH514 inhibits the expression of cell cycle-related proteins CDC2, Cyclin B1, Cyclin D1, Cyclin E1, and CMYC in Multiple Myeloma cells. SH514 can induce DNA damage and increase the expression of γH2AX. SH514 effectively inhibits the proliferation of multiple myeloma tumors .
Cat. No.: HY-P991148
CAS No.: 2983848-20-8
Target:
Research Areas:
Cat. No.: HY-167839
CAS No.: 2485758-49-2
(R)-JAK2/STAT3-IN-1 is a GP130 D1 domain inhibitor with anti-tumor activity. (R)-JAK2/STAT3-IN-1 can inhibit the phosphorylation of JAK2 and STAT3. The affinity of (R)-JAK2/STAT3-IN-1 for GP130 protein is 3.8 μM. (R)-JAK2/STAT3-IN-1 effectively inhibits the viability and migration of tumor cells and promotes apoptosis .
Cat. No.: HY-148611
CAS No.: 1135037-53-4
Target:
Research Areas:
NSC339614 potassium is a selective GluN1/GluN2C and GluN1/GluN2D receptor enhancer with the activity of enhancing neuronal responses to specific NMDA receptors. NSC339614 potassium can selectively enhance the signaling of GluN1/GluN2C and GluN1/GluN2D receptors without affecting other NMDA receptors. The mechanism of action of NSC339614 potassium does not compete with agonists of L-glutamate or glycine, nor does it depend on membrane potential. The activity of NSC339614 potassium depends on the specific structure of the agonist ligand binding domain, showing its potential as a novel pharmacological agent for studying the function of NMDA receptor subtypes and providing new lead compounds for a variety of neurological diseases .
Cat. No.: HY-103693R
CAS No.: 2809469-05-2
Target:
Research Areas:
NAZ2329 (Standard) is the analytical standard of NAZ2329 (HY-103693). This product is intended for research and analytical applications. NAZ2329, the first cell-permeable inhibitor of R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), allosterically and preferentially inhibits PTPRZ (IC50=7.5 µM for hPTPRZ1) and PTPRG (IC50=4.8 µM for hPTPRG) over other PTPs. NAZ2329 binds to the active D1 domain and more potently inhibits PTPRZ-D1 fragment (IC50 of 1.1 µM) than the whole intracellular (D1 + D2) fragment (IC50 of 7.5 µM). NAZ2329 can effectively inhibit tumor growth of the glioblastoma cells and suppress stem cell-like properties .
Cat. No.: HY-180900
CAS No.: 2249005-28-3
Target:
Research Areas:
Z3071585108 is a small molecule binder of the LAG-3 D1 domain with Kd values measured for the MST-TRIC channel and spectral shift detection of 59.2 and 56.1 μM respectively. Z3071585108 partially inhibits the binding of LAG-3 to MHCII, with an EC₅₀ of 42.9 μM. Z3071585108 can be used for the study of small molecule immunotherapies targeting LAG-3 .
Cat. No.: HY-P992254
Cat. No.: HY-181514
CAS No.: 3113051-34-3
STAT3-IN-53 (Compound L20) is a STAT3 inhibitor with a Kd value of 6.16 μM. STAT3-IN-53 binds directly to the SH2 domain of STAT3, inhibits phosphorylation at the Y705 site without affecting the total STAT3 protein level, and suppresses the IL-6/JAK/STAT3 pathway. STAT3-IN-53 downregulates the transcription and expression of cyclin-D1 and c-Myc. STAT3-IN-53 induces cell cycle arrest and promotes Apoptosis. STAT3-IN-53 exhibits anticancer activity against colorectal cancer .
Cat. No.: HY-184291
CAS No.: 3114314-82-5
Research Areas:
VCP/p97 IN-4 is a p97/VCP inhibitor (Kd=14.99 μM) targeting the allosteric site of the D1-D2 domain. VCP/p97 IN-4 inhibits the ATPase activity of VCP/p97 in an ATP concentration-independent manner. VCP/p97 IN-4 induces apoptosis, autophagy, mitochondrial stress and mitochondrial membrane depolarization. VCP/p97 IN-4 inhibits the growth of patient-derived colorectal cancer organoids and exhibits in vivo efficacy in a colorectal cancer xenograft mouse model. VCP/p97 IN-4 can be used for the research of colorectal cancer .
Cat. No.: HY-149590
CAS No.: 200348-48-7
Target:
Research Areas:
IPA is a specific Sec18/NSF inhibitor. IPA binds to phosphatidic acid competitively, induces conformational rigidification of Sec18/NSF, disrupts its essential flexibility, and blocks SNARE priming and vacuolar membrane fusion. IPA can be used to investigate the activity of Sec18 and SNARE priming kinetics .
Cat. No.: HY-P704032
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CSDE1; N-Ras Upstream Gene Protein; Cold Shock domain Containing E1; Upstream Of NRAS; D1S155E; NRAS-Related; UNR; Protein UNR; Cold Shock domain-Containing Protein E1; KIAA0885; Cold Shock domain Containing E1, RNA Binding; NRU
Cat. No.: HY-P70093
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: DCUN1D1; DCN1-Like Protein 1; Defective In Cullin Neddylation 1 domain Containing 1; DCNL1; DCUN1L1; DCN1, Defective In Cullin Neddylation 1, domain Containing 1 (S. Cerevisiae); SCCRO; DCN1, Defective In Cullin Neddylation 1, domain Containing 1; RP42; D
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
